@article { author = {}, title = {Metformin May Improve the Prognosis of Patients with Pancreatic Cancer}, journal = {Asian Pacific Journal of Cancer Prevention}, volume = {16}, number = {9}, pages = {3937-3940}, year = {2015}, publisher = {West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.}, issn = {1513-7368}, eissn = {2476-762X}, doi = {}, abstract = {Background: Pancreatic cancer risk is increased in patients with type 2 diabetes, while being reduced bymetformin treatment. However, it is unclear whether metformin could be associated with clinical outcomes ofpatients with pancreatic cancer and concurrent type 2 diabetes. Materials and Methods: A pooled analysis of4 publications including 1,429 patients was performed to investigate the association of metformin and overallsurvival(OS) in patients with pancreatic cancer and concurrent type 2 diabetes. Results: A borderline significantrelative survival benefit was found in metformin treated patients compared with non-metformin treated patients(hazard ratio 0.80; 95% CI: 0.62-1.03). Conclusions: These results suggest that further investigation is warrantedof whether metformin may benefit the survival of patients with pancreatic cancer and concurrent type 2 diabetes.}, keywords = {Pancreatic cancer,Metformin,survival,Prognosis}, url = {https://journal.waocp.org/article_31012.html}, eprint = {https://journal.waocp.org/article_31012_7c220f8137f19da9b6f9fb6dd7203398.pdf} }